Market Herald logo

Subscribe

Be the first with the news that moves the market

Biotech company Actinogen has expanded clinical development for the company’s lead drug candidate ‘Xanamem’.

The company made the decision after an extensive scientific, commercial and testing review of the drug showed positive projections.

Xanamem is a drug aimed at treating impairment in neurological diseases such as Alzheimer’s, schizophrenia and bipolar disorder.

The drug targets raised cortisol levels in the brain and inhibits excess production of it.

Excessive cortisol production in the brain is common amongst mood disorder patients.

Xanamem has shown positive results on genetically identical mouse models and showed maintained improved cognitive function for 41 weeks.

Second phase trials of Alzheimer’s patients using Xanamem began in 2017.

The company estimates roughly 24 million Americans are living with mood disorders and this research shows significant market opportunity.

A specialist advisory board will be assigned to establish the company’s future clinical development plan for the drug.

Please see announcement attached

ACW by the numbers
More From The Market Herald
The Market Herald Video

" Security Matters (ASX:SMX) enters into $2m standby equity facility

Security Matters (ASX:SMX) has entered into a standby equity deed with Evolution Capital.
The Market Herald Video

" Cynata Therapeutics (ASX:CYP) to conclude MEND trial following strategic review

Cynata Therapeutics (ASX:CYP) has completed a strategic review of its clinical development pipeline to maximise commercial…
The Market Herald Video

" AVITA Medical (ASX:AVH) reports positive results from soft tissue trial

AVITA Medical (ASX:AVH) reports positive top line results for its RECELL trial in patients with soft-tissue…
The Market Herald Video

" Archer Materials (ASX:AXE) secures Hong Kong patent for quantum computing chip

Archer Materials (ASX:AXE) announces the grant of a Hong Kong patent for its 12CQ quantum computing…